arrow
K

Koji Ando

kyushu university
H指数:34
被引数:3,770

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Longitudinal ctDNA profiling to guide anti-EGFR rechallenge in metastatic colorectal cancer: a prospective single-arm phase II trial

纵向ctDNA分析指导抗EGFR再挑战治疗在转移性结直肠癌中的应用:一项前瞻性单臂II期临床试验

2026-09-090
OAAI
ASO Author Reflections: Refining Borderline Resectability in ycT3 Esophageal Cancer with Tracheobronchial Contact: Clinical Utility of the Contact Angle

ASO作者反思:通过气管支气管接触角优化 ycT3 食管癌的临界可切除性:接触角的临床应用

2025-12-040
PRE
Prediction of Tracheobronchial Invasion in ycT3 Esophageal Cancer Using Contact Angle on Preoperative CT Images: A Multicenter Analysis

基于术前CT图像接触角预测ycT3食管癌气管支气管侵犯:一项多中心分析

2025-11-170
PRE
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery: A Prospective Cohort Study

分子残留病灶及复发在行术前手术的直肠癌患者中的研究:一项前瞻性队列研究

2025-09-260
OAAI
Prognostic Significance of Platelet-Lymphocyte Ratio (PLR) and Prognostic Nutritional Index (PNI) in Remnant Gastric Cancer: A Multicenter Retrospective Study

残胃癌症中血小板-淋巴细胞比值(PLR)和预后营养指数(PNI)的预后意义:一项多中心回顾性研究

2025-09-010
PRE
A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer

一项二期临床试验,评估在FOLFOXIRI联合贝伐珠单抗失败后,FOLFIRI联合阿柏西普对不可切除性转移性结直肠癌患者的疗效。

2025-02-010
PRE
ctDNA-based molecular residual disease and survival in resectable colorectal cancer

可切除结直肠癌中基于ctDNA的分子残留疾病和生存

2024-09-161
OAAI
Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study
2024-06-010
OAAI
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)

TP53基因的突变谱与晚期胃癌的nivolumab治疗效果相关 (TP53MUT研究)

2023-08-024
PRE
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
2021-06-157
OAAI